You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Alpha Cognition announces bioequivalence study results for Alzheimer’s

Alpha Cognition has announced positive results from a bioequivalence study with ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease (AD).